Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 133 | 2024 | 1074 | 19.520 |
Why?
|
Lung Neoplasms | 167 | 2024 | 2261 | 18.840 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 55 | 2024 | 2436 | 4.920 |
Why?
|
ErbB Receptors | 32 | 2023 | 485 | 3.960 |
Why?
|
Antibodies, Monoclonal, Humanized | 41 | 2024 | 930 | 3.630 |
Why?
|
Immunotherapy | 31 | 2024 | 629 | 3.580 |
Why?
|
Protein Kinase Inhibitors | 21 | 2023 | 589 | 3.510 |
Why?
|
Antineoplastic Agents, Immunological | 19 | 2023 | 185 | 3.500 |
Why?
|
B7-H1 Antigen | 32 | 2024 | 250 | 3.410 |
Why?
|
Antineoplastic Agents | 42 | 2023 | 2357 | 3.410 |
Why?
|
Antibodies, Monoclonal | 29 | 2024 | 1376 | 3.070 |
Why?
|
Quinazolines | 10 | 2021 | 220 | 3.060 |
Why?
|
Mutation | 41 | 2024 | 3967 | 2.860 |
Why?
|
Neoplasms | 24 | 2022 | 2897 | 2.710 |
Why?
|
Small Cell Lung Carcinoma | 12 | 2024 | 98 | 2.670 |
Why?
|
Thymus Neoplasms | 11 | 2023 | 41 | 2.200 |
Why?
|
Humans | 236 | 2024 | 86601 | 2.100 |
Why?
|
Thoracic Neoplasms | 7 | 2023 | 64 | 1.860 |
Why?
|
Pneumonia, Viral | 7 | 2020 | 316 | 1.670 |
Why?
|
Coronavirus Infections | 7 | 2020 | 301 | 1.670 |
Why?
|
Neoplasms, Glandular and Epithelial | 7 | 2022 | 74 | 1.530 |
Why?
|
Platinum | 14 | 2024 | 63 | 1.510 |
Why?
|
Molecular Targeted Therapy | 9 | 2021 | 266 | 1.500 |
Why?
|
Aged | 77 | 2023 | 18402 | 1.300 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 12 | 2024 | 154 | 1.300 |
Why?
|
Pandemics | 11 | 2021 | 740 | 1.260 |
Why?
|
Male | 96 | 2023 | 40956 | 1.240 |
Why?
|
Aged, 80 and over | 40 | 2021 | 6501 | 1.200 |
Why?
|
Mesothelioma | 8 | 2024 | 311 | 1.180 |
Why?
|
Female | 94 | 2023 | 44507 | 1.150 |
Why?
|
Pleural Neoplasms | 8 | 2024 | 188 | 1.140 |
Why?
|
Programmed Cell Death 1 Receptor | 8 | 2021 | 159 | 1.140 |
Why?
|
Patient Reported Outcome Measures | 6 | 2021 | 166 | 1.130 |
Why?
|
Biomarkers, Tumor | 19 | 2023 | 1464 | 1.120 |
Why?
|
Prognosis | 32 | 2022 | 3674 | 1.100 |
Why?
|
Italy | 17 | 2023 | 106 | 1.100 |
Why?
|
Registries | 6 | 2022 | 702 | 1.090 |
Why?
|
Etoposide | 9 | 2024 | 196 | 1.050 |
Why?
|
Drug Resistance, Neoplasm | 11 | 2022 | 592 | 1.040 |
Why?
|
Middle Aged | 69 | 2021 | 25017 | 1.030 |
Why?
|
Pemetrexed | 8 | 2023 | 76 | 1.020 |
Why?
|
Taxoids | 6 | 2020 | 129 | 1.010 |
Why?
|
Colorectal Neoplasms | 12 | 2021 | 938 | 1.000 |
Why?
|
Carcinoma, Squamous Cell | 9 | 2022 | 1075 | 0.990 |
Why?
|
Mutagenesis, Insertional | 2 | 2021 | 111 | 0.960 |
Why?
|
Receptor, ErbB-2 | 4 | 2021 | 223 | 0.950 |
Why?
|
Betacoronavirus | 7 | 2020 | 258 | 0.930 |
Why?
|
Neoplasm Staging | 19 | 2022 | 1937 | 0.890 |
Why?
|
Medical Oncology | 8 | 2023 | 359 | 0.870 |
Why?
|
Carcinoma, Large Cell | 3 | 2016 | 39 | 0.830 |
Why?
|
Carboplatin | 9 | 2023 | 286 | 0.820 |
Why?
|
Thymoma | 5 | 2023 | 30 | 0.800 |
Why?
|
Disease Progression | 16 | 2023 | 1531 | 0.790 |
Why?
|
Survival Rate | 21 | 2021 | 1860 | 0.790 |
Why?
|
Macrophages | 3 | 2019 | 554 | 0.790 |
Why?
|
Proto-Oncogene Proteins | 7 | 2021 | 645 | 0.790 |
Why?
|
Quality of Life | 11 | 2023 | 1583 | 0.790 |
Why?
|
Protein-Tyrosine Kinases | 7 | 2021 | 302 | 0.780 |
Why?
|
Piperazines | 4 | 2021 | 272 | 0.750 |
Why?
|
Adult | 51 | 2023 | 25640 | 0.740 |
Why?
|
Coronavirus | 1 | 2020 | 19 | 0.730 |
Why?
|
Receptor Protein-Tyrosine Kinases | 6 | 2023 | 153 | 0.720 |
Why?
|
Pyrimidines | 8 | 2023 | 370 | 0.700 |
Why?
|
Cisplatin | 8 | 2020 | 612 | 0.700 |
Why?
|
Paclitaxel | 3 | 2018 | 460 | 0.680 |
Why?
|
Follow-Up Studies | 17 | 2023 | 3636 | 0.680 |
Why?
|
Treatment Outcome | 31 | 2022 | 7988 | 0.680 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2018 | 19 | 0.670 |
Why?
|
Retrospective Studies | 35 | 2023 | 8475 | 0.670 |
Why?
|
Receptors, Fc | 1 | 2018 | 33 | 0.660 |
Why?
|
ras Proteins | 4 | 2015 | 128 | 0.650 |
Why?
|
Neuroendocrine Tumors | 2 | 2016 | 105 | 0.620 |
Why?
|
Survival Analysis | 15 | 2021 | 1538 | 0.620 |
Why?
|
Cholesterol | 1 | 2019 | 356 | 0.600 |
Why?
|
Genes, ras | 4 | 2012 | 96 | 0.600 |
Why?
|
Palliative Care | 4 | 2019 | 257 | 0.600 |
Why?
|
Carcinoma, Neuroendocrine | 2 | 2016 | 28 | 0.580 |
Why?
|
Bronchial Neoplasms | 1 | 2016 | 9 | 0.580 |
Why?
|
Receptors, Peptide | 1 | 2016 | 16 | 0.580 |
Why?
|
Carcinoid Tumor | 2 | 2016 | 42 | 0.580 |
Why?
|
Receptors, Somatostatin | 1 | 2016 | 33 | 0.570 |
Why?
|
Adenocarcinoma | 8 | 2022 | 1169 | 0.570 |
Why?
|
Erlotinib Hydrochloride | 7 | 2022 | 90 | 0.560 |
Why?
|
Genes, erbB-1 | 2 | 2015 | 16 | 0.560 |
Why?
|
Exons | 6 | 2023 | 450 | 0.540 |
Why?
|
DNA Mutational Analysis | 4 | 2016 | 526 | 0.540 |
Why?
|
Disease-Free Survival | 12 | 2020 | 1204 | 0.530 |
Why?
|
Angiogenesis Inhibitors | 5 | 2021 | 311 | 0.530 |
Why?
|
Radiopharmaceuticals | 1 | 2016 | 179 | 0.530 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 49 | 0.520 |
Why?
|
Health Services Accessibility | 1 | 2018 | 394 | 0.520 |
Why?
|
Metformin | 3 | 2024 | 128 | 0.500 |
Why?
|
Brain Neoplasms | 4 | 2022 | 763 | 0.490 |
Why?
|
Oncologists | 4 | 2021 | 36 | 0.490 |
Why?
|
Radiotherapy | 3 | 2021 | 328 | 0.490 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2023 | 137 | 0.470 |
Why?
|
Quinazolinones | 1 | 2013 | 13 | 0.450 |
Why?
|
Neuralgia | 1 | 2013 | 28 | 0.450 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2021 | 1197 | 0.450 |
Why?
|
Eye Diseases | 1 | 2013 | 53 | 0.450 |
Why?
|
Oxycodone | 1 | 2013 | 35 | 0.440 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2013 | 83 | 0.440 |
Why?
|
Chemoradiotherapy | 5 | 2022 | 301 | 0.430 |
Why?
|
Biological Products | 1 | 2014 | 143 | 0.430 |
Why?
|
Randomized Controlled Trials as Topic | 11 | 2021 | 864 | 0.430 |
Why?
|
Pyridazines | 2 | 2022 | 22 | 0.400 |
Why?
|
Piperidines | 3 | 2022 | 181 | 0.400 |
Why?
|
Immunohistochemistry | 11 | 2021 | 1753 | 0.390 |
Why?
|
Anti-Bacterial Agents | 3 | 2021 | 746 | 0.390 |
Why?
|
Bevacizumab | 6 | 2022 | 281 | 0.390 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2021 | 1313 | 0.390 |
Why?
|
Sequence Deletion | 1 | 2011 | 205 | 0.390 |
Why?
|
Liver Neoplasms | 4 | 2020 | 735 | 0.380 |
Why?
|
Nuclear Proteins | 4 | 2023 | 696 | 0.380 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2020 | 199 | 0.370 |
Why?
|
Platinum Compounds | 3 | 2019 | 31 | 0.370 |
Why?
|
Endonucleases | 3 | 2021 | 21 | 0.370 |
Why?
|
Tumor Burden | 3 | 2023 | 288 | 0.360 |
Why?
|
Fasting | 2 | 2021 | 161 | 0.360 |
Why?
|
Acrylamides | 3 | 2018 | 30 | 0.360 |
Why?
|
Signal Transduction | 3 | 2021 | 3241 | 0.350 |
Why?
|
Pneumonectomy | 3 | 2021 | 196 | 0.350 |
Why?
|
Interferons | 1 | 2010 | 133 | 0.350 |
Why?
|
Prospective Studies | 8 | 2023 | 4210 | 0.350 |
Why?
|
Aniline Compounds | 3 | 2018 | 55 | 0.350 |
Why?
|
Pneumonia | 2 | 2023 | 179 | 0.350 |
Why?
|
Carcinoma, Small Cell | 1 | 2010 | 134 | 0.350 |
Why?
|
Cohort Studies | 6 | 2022 | 2767 | 0.340 |
Why?
|
Kaplan-Meier Estimate | 8 | 2021 | 860 | 0.340 |
Why?
|
Biomarkers | 7 | 2023 | 1718 | 0.340 |
Why?
|
Smoking | 2 | 2016 | 609 | 0.330 |
Why?
|
DNA-Binding Proteins | 4 | 2021 | 1208 | 0.320 |
Why?
|
Double-Blind Method | 4 | 2021 | 1823 | 0.320 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2018 | 468 | 0.320 |
Why?
|
Cell Line, Tumor | 7 | 2021 | 2426 | 0.310 |
Why?
|
Neoplasm Metastasis | 8 | 2020 | 1056 | 0.300 |
Why?
|
Time Factors | 8 | 2021 | 5209 | 0.300 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2023 | 456 | 0.280 |
Why?
|
Combined Modality Therapy | 5 | 2021 | 1685 | 0.280 |
Why?
|
Cetuximab | 8 | 2012 | 113 | 0.280 |
Why?
|
Models, Statistical | 1 | 2009 | 574 | 0.270 |
Why?
|
Steroids | 3 | 2022 | 177 | 0.270 |
Why?
|
Stomach Neoplasms | 1 | 2008 | 266 | 0.260 |
Why?
|
Bone Neoplasms | 2 | 2023 | 322 | 0.260 |
Why?
|
Transcription Factors | 4 | 2023 | 1565 | 0.260 |
Why?
|
Young Adult | 11 | 2021 | 5974 | 0.260 |
Why?
|
Diarrhea | 2 | 2018 | 182 | 0.260 |
Why?
|
Lung | 6 | 2023 | 1170 | 0.260 |
Why?
|
Europe | 6 | 2021 | 309 | 0.260 |
Why?
|
Pyrazoles | 2 | 2018 | 153 | 0.250 |
Why?
|
Gene Dosage | 2 | 2016 | 207 | 0.250 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 3 | 2019 | 56 | 0.240 |
Why?
|
Global Burden of Disease | 2 | 2020 | 10 | 0.240 |
Why?
|
Salvage Therapy | 3 | 2021 | 233 | 0.240 |
Why?
|
DNA Repair | 2 | 2016 | 356 | 0.240 |
Why?
|
Telemedicine | 3 | 2021 | 169 | 0.230 |
Why?
|
Pleura | 2 | 2024 | 30 | 0.230 |
Why?
|
Circulating Tumor DNA | 1 | 2023 | 37 | 0.220 |
Why?
|
Adrenal Cortex Hormones | 2 | 2021 | 263 | 0.220 |
Why?
|
CTLA-4 Antigen | 3 | 2019 | 135 | 0.220 |
Why?
|
Thymectomy | 1 | 2022 | 31 | 0.220 |
Why?
|
Animals | 13 | 2024 | 26581 | 0.220 |
Why?
|
Colonic Neoplasms | 2 | 2006 | 556 | 0.220 |
Why?
|
In Situ Hybridization, Fluorescence | 4 | 2016 | 348 | 0.220 |
Why?
|
Severity of Illness Index | 3 | 2021 | 1801 | 0.220 |
Why?
|
Tumor Suppressor Proteins | 2 | 2015 | 279 | 0.210 |
Why?
|
Autoimmune Diseases | 2 | 2022 | 241 | 0.210 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2018 | 458 | 0.210 |
Why?
|
Societies, Medical | 3 | 2021 | 572 | 0.210 |
Why?
|
Cytokines | 3 | 2021 | 776 | 0.210 |
Why?
|
Mice, Nude | 3 | 2018 | 790 | 0.210 |
Why?
|
Myasthenia Gravis | 1 | 2022 | 83 | 0.210 |
Why?
|
Fatty Acids | 1 | 2022 | 130 | 0.210 |
Why?
|
Disease Management | 3 | 2021 | 327 | 0.210 |
Why?
|
Extracellular Vesicles | 1 | 2022 | 42 | 0.210 |
Why?
|
Inflammation Mediators | 1 | 2022 | 154 | 0.200 |
Why?
|
Clinical Decision-Making | 2 | 2021 | 257 | 0.200 |
Why?
|
Health Status Disparities | 1 | 2023 | 170 | 0.200 |
Why?
|
Compassionate Use Trials | 1 | 2021 | 8 | 0.200 |
Why?
|
Risk Factors | 7 | 2021 | 5416 | 0.200 |
Why?
|
Research | 1 | 2022 | 253 | 0.200 |
Why?
|
Tubulin Modulators | 1 | 2021 | 24 | 0.200 |
Why?
|
Immunosenescence | 1 | 2020 | 4 | 0.190 |
Why?
|
Immunologic Factors | 2 | 2019 | 170 | 0.190 |
Why?
|
Myeloid Cells | 1 | 2021 | 98 | 0.190 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2020 | 32 | 0.190 |
Why?
|
Pyridines | 3 | 2021 | 309 | 0.190 |
Why?
|
Adolescent | 7 | 2023 | 8979 | 0.190 |
Why?
|
Deoxycytidine | 1 | 2021 | 237 | 0.190 |
Why?
|
Information Dissemination | 1 | 2021 | 103 | 0.190 |
Why?
|
Patient Care Management | 1 | 2020 | 31 | 0.180 |
Why?
|
Leadership | 1 | 2021 | 134 | 0.180 |
Why?
|
Radiation Oncology | 1 | 2021 | 119 | 0.180 |
Why?
|
Decision Support Techniques | 1 | 2021 | 160 | 0.180 |
Why?
|
Critical Pathways | 1 | 2019 | 35 | 0.180 |
Why?
|
Social Media | 1 | 2021 | 79 | 0.170 |
Why?
|
International Cooperation | 4 | 2020 | 127 | 0.170 |
Why?
|
Carcinoma, Bronchogenic | 1 | 2019 | 30 | 0.170 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 1034 | 0.170 |
Why?
|
Cause of Death | 1 | 2020 | 277 | 0.170 |
Why?
|
Vaccination | 1 | 2021 | 254 | 0.170 |
Why?
|
Circulating MicroRNA | 1 | 2019 | 12 | 0.170 |
Why?
|
Infection Control | 1 | 2020 | 115 | 0.170 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 1621 | 0.170 |
Why?
|
Nausea | 2 | 2013 | 175 | 0.170 |
Why?
|
Consensus | 1 | 2020 | 335 | 0.170 |
Why?
|
Antibodies, Blocking | 1 | 2018 | 21 | 0.170 |
Why?
|
Vomiting | 2 | 2013 | 193 | 0.170 |
Why?
|
Drug Approval | 1 | 2019 | 62 | 0.160 |
Why?
|
Injection Site Reaction | 1 | 2018 | 2 | 0.160 |
Why?
|
Inflammation | 2 | 2021 | 920 | 0.160 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2019 | 71 | 0.160 |
Why?
|
gamma-Glutamyltransferase | 1 | 2018 | 16 | 0.160 |
Why?
|
4-Butyrolactone | 1 | 2018 | 2 | 0.160 |
Why?
|
MicroRNAs | 2 | 2021 | 534 | 0.160 |
Why?
|
Neoplasms, Second Primary | 1 | 2021 | 252 | 0.160 |
Why?
|
Ambulatory Care | 1 | 2019 | 181 | 0.160 |
Why?
|
Sarcoma | 1 | 2020 | 211 | 0.160 |
Why?
|
Toll-Like Receptor 4 | 1 | 2018 | 88 | 0.160 |
Why?
|
Aspartate Aminotransferases | 1 | 2018 | 73 | 0.160 |
Why?
|
Biomedical Research | 2 | 2021 | 375 | 0.160 |
Why?
|
Mice, SCID | 1 | 2018 | 252 | 0.160 |
Why?
|
Mobile Applications | 1 | 2019 | 63 | 0.160 |
Why?
|
Niacinamide | 1 | 2018 | 116 | 0.160 |
Why?
|
Stress, Psychological | 1 | 2021 | 313 | 0.160 |
Why?
|
Skin Diseases | 1 | 2019 | 166 | 0.160 |
Why?
|
Hospitalization | 2 | 2020 | 848 | 0.150 |
Why?
|
Organoplatinum Compounds | 4 | 2016 | 94 | 0.150 |
Why?
|
Pulmonary Medicine | 1 | 2018 | 46 | 0.150 |
Why?
|
Phenylurea Compounds | 1 | 2018 | 113 | 0.150 |
Why?
|
Sodium | 1 | 2018 | 341 | 0.150 |
Why?
|
Monitoring, Physiologic | 1 | 2019 | 268 | 0.150 |
Why?
|
NF-kappa B | 1 | 2020 | 444 | 0.150 |
Why?
|
Cytoskeletal Proteins | 1 | 2018 | 223 | 0.150 |
Why?
|
Multiple Sclerosis | 1 | 2019 | 262 | 0.150 |
Why?
|
Fatigue | 1 | 2018 | 174 | 0.150 |
Why?
|
Thrombosis | 1 | 2020 | 296 | 0.150 |
Why?
|
Referral and Consultation | 1 | 2019 | 326 | 0.150 |
Why?
|
Longitudinal Studies | 1 | 2020 | 1019 | 0.150 |
Why?
|
Melanoma | 1 | 2021 | 454 | 0.150 |
Why?
|
Patient Selection | 4 | 2021 | 685 | 0.140 |
Why?
|
Research Design | 2 | 2018 | 594 | 0.140 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2018 | 276 | 0.140 |
Why?
|
Radiosurgery | 1 | 2020 | 272 | 0.140 |
Why?
|
Cancer Vaccines | 1 | 2018 | 156 | 0.140 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2018 | 302 | 0.140 |
Why?
|
Clinical Trials as Topic | 7 | 2018 | 1169 | 0.140 |
Why?
|
DNA Damage | 1 | 2018 | 366 | 0.140 |
Why?
|
Recurrence | 2 | 2017 | 1139 | 0.140 |
Why?
|
Cell Cycle Checkpoints | 1 | 2016 | 63 | 0.140 |
Why?
|
Cytodiagnosis | 1 | 2016 | 42 | 0.140 |
Why?
|
DNA Copy Number Variations | 1 | 2016 | 171 | 0.130 |
Why?
|
Cognitive Dysfunction | 1 | 2017 | 132 | 0.130 |
Why?
|
Cell Cycle Proteins | 1 | 2018 | 388 | 0.130 |
Why?
|
Proportional Hazards Models | 4 | 2021 | 857 | 0.130 |
Why?
|
Gases | 1 | 2014 | 30 | 0.120 |
Why?
|
Breast Neoplasms | 2 | 2021 | 2887 | 0.120 |
Why?
|
Portal Vein | 1 | 2014 | 120 | 0.120 |
Why?
|
Case-Control Studies | 1 | 2018 | 1804 | 0.120 |
Why?
|
Thoracic Surgical Procedures | 1 | 2014 | 44 | 0.120 |
Why?
|
Breast Neoplasms, Male | 1 | 2013 | 30 | 0.120 |
Why?
|
Pregabalin | 1 | 2013 | 6 | 0.120 |
Why?
|
Surveys and Questionnaires | 4 | 2023 | 2501 | 0.110 |
Why?
|
Neurokinin-1 Receptor Antagonists | 1 | 2013 | 34 | 0.110 |
Why?
|
Eye | 1 | 2013 | 111 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2015 | 1961 | 0.110 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2013 | 150 | 0.110 |
Why?
|
Gene Amplification | 1 | 2012 | 131 | 0.100 |
Why?
|
Caloric Restriction | 2 | 2024 | 14 | 0.100 |
Why?
|
Fluorouracil | 3 | 2012 | 556 | 0.100 |
Why?
|
Stents | 1 | 2014 | 377 | 0.100 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 469 | 0.100 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2013 | 291 | 0.100 |
Why?
|
Polypharmacy | 2 | 2021 | 15 | 0.100 |
Why?
|
Mastectomy | 1 | 2013 | 236 | 0.100 |
Why?
|
Forecasting | 2 | 2009 | 304 | 0.100 |
Why?
|
Proton Pump Inhibitors | 2 | 2021 | 31 | 0.100 |
Why?
|
Communicable Disease Control | 2 | 2021 | 51 | 0.100 |
Why?
|
Topotecan | 1 | 2010 | 45 | 0.100 |
Why?
|
Drug Therapy, Combination | 1 | 2013 | 894 | 0.100 |
Why?
|
Psychotherapy | 1 | 2011 | 74 | 0.090 |
Why?
|
Camptothecin | 2 | 2012 | 189 | 0.090 |
Why?
|
Ovarian Neoplasms | 1 | 2016 | 744 | 0.090 |
Why?
|
Multicenter Studies as Topic | 2 | 2021 | 159 | 0.090 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 418 | 0.090 |
Why?
|
Risk Assessment | 4 | 2021 | 2261 | 0.090 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2021 | 172 | 0.090 |
Why?
|
Precision Medicine | 1 | 2013 | 395 | 0.090 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2023 | 262 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 4 | 2020 | 2600 | 0.090 |
Why?
|
Jaw Diseases | 1 | 2008 | 7 | 0.080 |
Why?
|
Health Personnel | 2 | 2021 | 202 | 0.080 |
Why?
|
Osteonecrosis | 1 | 2008 | 21 | 0.080 |
Why?
|
Hematinics | 1 | 2008 | 11 | 0.080 |
Why?
|
Diphosphonates | 1 | 2008 | 36 | 0.080 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 2356 | 0.080 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2019 | 176 | 0.080 |
Why?
|
Blepharoptosis | 1 | 2007 | 11 | 0.080 |
Why?
|
Bone Density Conservation Agents | 1 | 2008 | 45 | 0.080 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 916 | 0.080 |
Why?
|
Erythropoietin | 1 | 2008 | 91 | 0.080 |
Why?
|
Neurotoxicity Syndromes | 1 | 2007 | 28 | 0.080 |
Why?
|
Meta-Analysis as Topic | 2 | 2013 | 87 | 0.080 |
Why?
|
Imidazoles | 1 | 2008 | 162 | 0.080 |
Why?
|
Biopsy | 2 | 2023 | 1161 | 0.080 |
Why?
|
Mental Disorders | 1 | 2011 | 371 | 0.080 |
Why?
|
Anemia | 1 | 2008 | 128 | 0.070 |
Why?
|
Postoperative Care | 1 | 2008 | 221 | 0.070 |
Why?
|
Gene Expression | 3 | 2021 | 1284 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2021 | 1673 | 0.070 |
Why?
|
Genotype | 3 | 2015 | 1850 | 0.070 |
Why?
|
Perioperative Care | 1 | 2008 | 161 | 0.070 |
Why?
|
Drug Delivery Systems | 1 | 2008 | 178 | 0.070 |
Why?
|
Antiemetics | 1 | 2007 | 98 | 0.070 |
Why?
|
NIH 3T3 Cells | 2 | 2016 | 105 | 0.070 |
Why?
|
Fatal Outcome | 2 | 2017 | 293 | 0.070 |
Why?
|
Floxuridine | 1 | 2005 | 11 | 0.070 |
Why?
|
United States | 3 | 2023 | 6665 | 0.070 |
Why?
|
Foot | 1 | 2005 | 50 | 0.060 |
Why?
|
Dermatitis | 1 | 2005 | 32 | 0.060 |
Why?
|
Mice | 4 | 2024 | 11352 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2010 | 645 | 0.060 |
Why?
|
Anxiety | 2 | 2021 | 287 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2008 | 532 | 0.060 |
Why?
|
Hand | 1 | 2005 | 130 | 0.060 |
Why?
|
Liquid Biopsy | 1 | 2023 | 33 | 0.060 |
Why?
|
Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 11 | 0.060 |
Why?
|
European Union | 1 | 2023 | 8 | 0.060 |
Why?
|
North America | 1 | 2023 | 180 | 0.060 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2023 | 41 | 0.060 |
Why?
|
Tetraspanins | 1 | 2022 | 1 | 0.060 |
Why?
|
Tetraspanin 28 | 1 | 2022 | 3 | 0.060 |
Why?
|
DNA Helicases | 1 | 2023 | 79 | 0.060 |
Why?
|
Armed Conflicts | 1 | 2022 | 1 | 0.060 |
Why?
|
Ukraine | 1 | 2022 | 14 | 0.060 |
Why?
|
Adjuvants, Immunologic | 1 | 2023 | 167 | 0.050 |
Why?
|
Comorbidity | 2 | 2020 | 943 | 0.050 |
Why?
|
Oncogene Addiction | 1 | 2022 | 2 | 0.050 |
Why?
|
Uncertainty | 1 | 2022 | 71 | 0.050 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2022 | 40 | 0.050 |
Why?
|
Survivors | 1 | 2023 | 226 | 0.050 |
Why?
|
Norway | 1 | 2021 | 8 | 0.050 |
Why?
|
Authorship | 1 | 2021 | 24 | 0.050 |
Why?
|
Spain | 1 | 2021 | 33 | 0.050 |
Why?
|
Biology | 1 | 2021 | 50 | 0.050 |
Why?
|
Oncology Nursing | 1 | 2021 | 8 | 0.050 |
Why?
|
Netherlands | 1 | 2021 | 19 | 0.050 |
Why?
|
Ligands | 1 | 2022 | 433 | 0.050 |
Why?
|
Neoadjuvant Therapy | 1 | 2023 | 317 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 879 | 0.050 |
Why?
|
Autoantibodies | 1 | 2022 | 267 | 0.050 |
Why?
|
Carbazoles | 1 | 2021 | 51 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2022 | 190 | 0.050 |
Why?
|
Organophosphorus Compounds | 1 | 2021 | 55 | 0.050 |
Why?
|
Epidemics | 1 | 2021 | 33 | 0.050 |
Why?
|
Personal Protective Equipment | 1 | 2021 | 32 | 0.050 |
Why?
|
Antigen-Antibody Complex | 1 | 2021 | 87 | 0.050 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 1 | 2020 | 8 | 0.050 |
Why?
|
Neutrophils | 1 | 2022 | 307 | 0.050 |
Why?
|
Drug Interactions | 1 | 2021 | 248 | 0.050 |
Why?
|
United Kingdom | 1 | 2021 | 164 | 0.050 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2020 | 70 | 0.050 |
Why?
|
Incidence | 2 | 2019 | 1576 | 0.050 |
Why?
|
Intersectoral Collaboration | 1 | 2020 | 10 | 0.050 |
Why?
|
Fear | 1 | 2021 | 78 | 0.050 |
Why?
|
China | 1 | 2021 | 228 | 0.050 |
Why?
|
Child | 2 | 2022 | 6926 | 0.050 |
Why?
|
Disease Susceptibility | 1 | 2021 | 193 | 0.050 |
Why?
|
Lymphocytes | 1 | 2022 | 464 | 0.050 |
Why?
|
Edema | 1 | 2020 | 71 | 0.050 |
Why?
|
Leucovorin | 2 | 2012 | 218 | 0.050 |
Why?
|
Artificial Intelligence | 1 | 2023 | 298 | 0.050 |
Why?
|
Health Surveys | 1 | 2021 | 239 | 0.050 |
Why?
|
Patient Preference | 1 | 2021 | 105 | 0.050 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2020 | 165 | 0.050 |
Why?
|
Mice, Transgenic | 1 | 2024 | 1540 | 0.050 |
Why?
|
Mortality | 1 | 2021 | 149 | 0.050 |
Why?
|
Public Health | 1 | 2021 | 129 | 0.040 |
Why?
|
Immunity | 1 | 2020 | 136 | 0.040 |
Why?
|
Qualitative Research | 1 | 2021 | 256 | 0.040 |
Why?
|
Global Health | 1 | 2021 | 193 | 0.040 |
Why?
|
Sex Factors | 1 | 2023 | 1054 | 0.040 |
Why?
|
Phenotype | 2 | 2016 | 2377 | 0.040 |
Why?
|
Administration, Metronomic | 1 | 2019 | 2 | 0.040 |
Why?
|
Retreatment | 1 | 2019 | 107 | 0.040 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2020 | 273 | 0.040 |
Why?
|
Interdisciplinary Communication | 1 | 2020 | 130 | 0.040 |
Why?
|
Adenosine | 1 | 2022 | 225 | 0.040 |
Why?
|
International Agencies | 1 | 2019 | 34 | 0.040 |
Why?
|
Outpatients | 1 | 2019 | 94 | 0.040 |
Why?
|
Gene Rearrangement | 1 | 2020 | 170 | 0.040 |
Why?
|
Diet Therapy | 1 | 2018 | 20 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2020 | 315 | 0.040 |
Why?
|
Expert Testimony | 1 | 2019 | 46 | 0.040 |
Why?
|
Hyponatremia | 1 | 2018 | 25 | 0.040 |
Why?
|
Microsatellite Instability | 1 | 2019 | 43 | 0.040 |
Why?
|
Cell Growth Processes | 1 | 2018 | 83 | 0.040 |
Why?
|
Paris | 1 | 2018 | 5 | 0.040 |
Why?
|
Karnofsky Performance Status | 1 | 2018 | 40 | 0.040 |
Why?
|
Azacitidine | 1 | 2019 | 137 | 0.040 |
Why?
|
Biomarkers, Pharmacological | 1 | 2017 | 22 | 0.040 |
Why?
|
Drug Synergism | 1 | 2018 | 303 | 0.040 |
Why?
|
Oncogenes | 1 | 2018 | 88 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2009 | 1720 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2018 | 36 | 0.040 |
Why?
|
Gene Deletion | 1 | 2018 | 329 | 0.040 |
Why?
|
Standard of Care | 1 | 2018 | 78 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2018 | 116 | 0.040 |
Why?
|
Social Networking | 1 | 2018 | 75 | 0.040 |
Why?
|
Proteomics | 1 | 2018 | 212 | 0.040 |
Why?
|
Venous Thrombosis | 1 | 2020 | 243 | 0.040 |
Why?
|
Patient Safety | 1 | 2019 | 212 | 0.040 |
Why?
|
Gene Duplication | 1 | 2017 | 125 | 0.040 |
Why?
|
Immunosuppressive Agents | 1 | 2022 | 977 | 0.040 |
Why?
|
5' Untranslated Regions | 1 | 2016 | 49 | 0.040 |
Why?
|
Transfection | 1 | 2018 | 896 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 559 | 0.040 |
Why?
|
Pharmacogenomic Variants | 1 | 2016 | 41 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2017 | 429 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2019 | 451 | 0.040 |
Why?
|
Genomic Instability | 1 | 2016 | 79 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 56 | 0.030 |
Why?
|
Asbestos | 1 | 2015 | 22 | 0.030 |
Why?
|
Genes, Neoplasm | 1 | 2015 | 37 | 0.030 |
Why?
|
GPI-Linked Proteins | 1 | 2015 | 50 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2018 | 353 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 115 | 0.030 |
Why?
|
3' Untranslated Regions | 1 | 2015 | 92 | 0.030 |
Why?
|
Proteasome Inhibitors | 1 | 2015 | 51 | 0.030 |
Why?
|
Staining and Labeling | 1 | 2016 | 165 | 0.030 |
Why?
|
Carcinogens | 1 | 2015 | 108 | 0.030 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2015 | 85 | 0.030 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2016 | 214 | 0.030 |
Why?
|
Cation Transport Proteins | 1 | 2015 | 64 | 0.030 |
Why?
|
Decision Making | 1 | 2021 | 642 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2021 | 1578 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2021 | 2378 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2021 | 2705 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2015 | 425 | 0.030 |
Why?
|
Colonic Diseases | 1 | 2014 | 65 | 0.030 |
Why?
|
Blotting, Western | 1 | 2015 | 782 | 0.030 |
Why?
|
Pregnancy | 1 | 2021 | 2893 | 0.030 |
Why?
|
Intestinal Obstruction | 1 | 2014 | 88 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2016 | 751 | 0.030 |
Why?
|
Cell Cycle | 1 | 2015 | 502 | 0.030 |
Why?
|
SEER Program | 1 | 2014 | 184 | 0.030 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2013 | 12 | 0.030 |
Why?
|
Contrast Media | 1 | 2018 | 1077 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2015 | 456 | 0.030 |
Why?
|
Carcinosarcoma | 1 | 2013 | 20 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2018 | 426 | 0.030 |
Why?
|
Cell Survival | 1 | 2015 | 969 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 1384 | 0.030 |
Why?
|
Medical Records | 1 | 2013 | 119 | 0.030 |
Why?
|
DNA, Neoplasm | 1 | 2013 | 265 | 0.030 |
Why?
|
Databases, Factual | 1 | 2016 | 812 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2016 | 819 | 0.030 |
Why?
|
Odds Ratio | 1 | 2014 | 678 | 0.030 |
Why?
|
Receptors, Progesterone | 1 | 2013 | 167 | 0.030 |
Why?
|
Germany | 1 | 2012 | 72 | 0.030 |
Why?
|
Radiography | 1 | 2014 | 813 | 0.030 |
Why?
|
Alleles | 1 | 2015 | 1127 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2022 | 2207 | 0.030 |
Why?
|
Apoptosis | 1 | 2018 | 1683 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2013 | 384 | 0.030 |
Why?
|
Glutamates | 1 | 2011 | 89 | 0.030 |
Why?
|
Adjustment Disorders | 1 | 2011 | 6 | 0.020 |
Why?
|
Triple Negative Breast Neoplasms | 1 | 2013 | 137 | 0.020 |
Why?
|
Causality | 1 | 2011 | 81 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2016 | 2818 | 0.020 |
Why?
|
Guanine | 1 | 2011 | 208 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2012 | 294 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 427 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2011 | 131 | 0.020 |
Why?
|
Anxiety Disorders | 1 | 2011 | 148 | 0.020 |
Why?
|
Needs Assessment | 1 | 2011 | 154 | 0.020 |
Why?
|
Depressive Disorder | 1 | 2011 | 218 | 0.020 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2011 | 96 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2015 | 1458 | 0.020 |
Why?
|
Genetic Markers | 1 | 2010 | 476 | 0.020 |
Why?
|
Social Support | 1 | 2011 | 193 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2011 | 999 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 1565 | 0.020 |
Why?
|
Darbepoetin alfa | 1 | 2008 | 5 | 0.020 |
Why?
|
Hemoglobins | 1 | 2008 | 179 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2010 | 429 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 2270 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2007 | 244 | 0.020 |
Why?
|
Depression | 1 | 2011 | 473 | 0.020 |
Why?
|
Pilot Projects | 1 | 2008 | 839 | 0.020 |
Why?
|
X-Ray Film | 1 | 2005 | 36 | 0.020 |
Why?
|
Infusions, Intra-Arterial | 1 | 2005 | 34 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2010 | 1981 | 0.020 |
Why?
|
Syndrome | 1 | 2005 | 446 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2008 | 508 | 0.010 |
Why?
|
Catheterization | 1 | 2005 | 232 | 0.010 |
Why?
|